Clinical Trial Update: Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports safety and efficacy results for IDEC-114 in combination with Rituxan in non-Hodgkin lymphoma, with the Phase 1/2 study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• IDEC-114
• Rituxan (rituximab)

Snippet

Sponsor: Biogen | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED